drugset / Trial / NCT03979820

A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure

NCT03979820

Phase 1 Terminated 53 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once daily compared to placebo and phenelzine (Nardil®) as positive control.

Timeline

Start
2019-07-31
Primary completion
2020-04-08
Completion
2020-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1467335 Unknown 10 mg
Subject BI 1467335 Unknown 15 mg
Comparator Phenelzine Small molecule
Subject Tyramine Small molecule

Indications

No indication recorded.